Background: Work‐related skin diseases (WSD) are caused or worsened by a professional activity. Occupational skin diseases (OSD) need to fulfil additional legal criteria which differ from country to country. OSD range amongst the five most frequently notified occupational diseases (musculoskeletal diseases, neurologic diseases, lung diseases, diseases of the sensory organs, skin diseases) in Europe.Objective: To retrieve information and compare the current state of national frameworks and pathways to manage patients with occupational skin disease with regard to prevention, diagnosis, treatment and rehabilitation in different European countries.Methods: A questionnaire‐based survey of the current situation regarding OSD patient management pathways was carried out with experts on occupational dermatology and/or occupational medicine from 28 European countries contributing to the European Cooperation in Science and Technology (COST) Action TD 1206 (StanDerm) (www.standerm.eu).Results: Besides a national health service or a statutory health insurance, most European member states implemented a second insurance scheme specifically geared at occupational diseases [insurance against occupational risks (synonyms: insurance against work accidents and occupational injuries; statutory social accident insurance)]. Legal standards for the assessment of occupationally triggered diseases with a genetic background differ between different countries, however, in most European member states recognition as OSD is possible. In one‐third of the countries UV light‐induced tumours can be recognized as OSD under specific conditions.Conclusion: OSD definitions vary between European countries and are not directly comparable, which hampers comparisons between statistics collected in different countries. Awareness of this fact and further efforts for standardization are necessary.
17 March 2016 in Journal of the European Academy of Dermatology and Venereology
The presented article studies the role of selected inflammatory and anti-inflammatory serum markers of psoriatic patients in the pathogenesis of metabolic syndrome (MS) and psoriasis. The study is based on the comparison between the group of psoriatic patients (74) and the control group (65). We found significantly higher BMI () and diastolic blood pressure () in the psoriatic patients. The values of waist circumference and BMI were significantly higher () in the male patients compared to the men in the control group. The analysis revealed significantly higher CRP (), Lp-PLA2 (), leptin (), and resistin () levels in the psoriatic patients. Significantly higher levels of CRP (), Lp-PLA2 (), leptin (), and resistin () were found in the patients with MS compared to the controls with MS. The level of adiponectin was significantly lower () in the patients with MS. Finally, we found significantly higher level of Lp-PLA2 () in the group of patients without MS compared to the controls without MS. In conclusion, observed inflammatory and anti-inflammatory markers (CRP, adiponectin, leptin, resistin, and Lp-PLA2) are involved in both pathogenesis of MS and pathogenesis of psoriasis. The level of Lp-PLA2 indicates the presence of subclinical atherosclerosis (cardiovascular risk) in psoriatic patients.
10 December 2014 in Journal of the European Academy of Dermatology and Venereology